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cause the D-allele was associated with significant, co-dominantInteracting effects of gender and genotype on blood pressure
increases in serum ACE activity in both genders, the gender-response to hydrochlorothiazide.
specific effects of the I/D polymorphism on BP response toBackground. Genetic factors may influence blood pressure
HCTZ may be mediated subsequent to the enzymatic genera-(BP) response to diuretic therapy through their effects on activ-
tion of angiotensin II.ity of the renin-angiotensin-aldosterone system (RAAS). The
insertion/deletion (I/D) polymorphism of the angiotensin-con-
verting enzyme (ACE) gene is associated with variation in
serum ACE activity and may influence BP in a gender-specific
Thiazide diuretics are one of the preferred initial ther-manner.
apies for uncomplicated hypertension [1]. Hydrochloro-Methods. We measured the I/D polymorphism in 206 non-
Hispanic women (130 blacks, 76 whites) and 170 non-Hispanic thiazide (HCTZ) is the most commonly prescribed drug
men (62 blacks, 108 whites) with essential hypertension (age in this class. Older age, black race, and measures of
48  7 years, mean  SD) who underwent monotherapy with the renin-angiotensin-aldosterone system (RAAS) arehydrochlorothiazide (HCTZ) 25 mg daily for four weeks.
established predictors of the blood pressure (BP) low-Results. In both genders, serum ACE activity increased in
ering response to HCTZ [2–5]. Because measures of thea co-dominant fashion in association with the D-allele (P 
0.001 for both genders). In regression models that considered RAAS are predictors of response to HCTZ, variation
the effects of baseline BP, race, gender, age, waist-to-hip ratio, in genes encoding components of this system might also
and measures of the RAAS, there was significant interaction predict response.between the effects of the ACE genotype and gender on the
An insertion/deletion (I/D) polymorphism in intron 16responses of both systolic and diastolic BP to HCTZ (for sys-
of the gene encoding for angiotensin-converting enzymetolic BP response, P  0.03; for diastolic BP response, P 
0.001). Among women, mean declines in systolic and diastolic (ACE) has been associated with differences in ACE
BP were greater in II than in DD homozygotes; whereas among activity, which increases in a co-dominant fashion with
men, mean declines in systolic and diastolic BP were greater
the deletion allele [6]. The deletion allele also has beenin DD than in II homozygotes. In models that included the
associated with several cardiovascular phenotypes in-effects of race, gender, age, and waist-to-hip ratio, there was
also significant interaction between the effects of the ACE cluding higher BP levels and greater risk of target organ
genotype and gender on pre-treatment urinary aldosterone complications in hypertensive individuals [7–10]. In large
excretion (P  0.01) and change in urinary aldosterone excre- samples, the observed associations have frequently been
tion in response to HCTZ (P  0.007). The genotypes that
gender-specific suggesting interaction between the ef-were associated with the greatest BP responses to HCTZ (II
fects of the I/D polymorphism and gender [11–13].homozygotes in women and DD homozygotes in men) had the
lowest pre-treatment urinary aldosterone excretion and the The purpose of the present study was to evaluate the
greatest increase in urinary aldosterone excretion in response relationship between the ACE I/D polymorphism and
to HCTZ. interindividual variation in BP response to HCTZ inConclusion. The relationship between the ACE I/D poly-
non-Hispanic women and men with essential hyperten-morphism and antihypertensive response to a standard dose
of HCTZ differs significantly between women and men. Be- sion.
Key words: hypertension, blood pressure, diuretic, genetics, ACE I/D METHODS
polymorphism, thiazide diuretics, aldosterone excretion.
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Table 1. Relative frequencies of genotypes and allelesbetween 30- and 59.9-years-old and had previously diag-
nosed hypertension. The non-Hispanic black subjects Genotypes % Alleles %
(from Atlanta, GA) and the non-Hispanic white subjects Race Gender N DD DI II D I
(from Rochester, MN) were participants in an ongoing
Black Female 130 28.5 58.5 13.0 57.7 42.3
study to identify predictors of BP response to diuretic Male 62 30.6 48.4 21.0 54.8 45.2
Pooled 192 29.2 55.2 15.6 56.8 43.2therapy [14]. Subjects had to have a BP of 180/110
White Female 76 32.9 44.7 22.4 55.3 44.7mm Hg, be in good general health, and be able to discon-
Male 108 25.9 47.2 26.9 49.5 50.5
tinue drugs that could influence BP level, the renin- Pooled 184 28.8 46.2 25.0 51.9 48.1
angiotensin-aldosterone system (RAAS), or antagonize Genotype and allele frequencies did not differ significantly between races
(P  0.10 for genotype frequency in each gender; P  0.35 for allele frequencythe effect of thiazide diuretics. However, postmeno-
in each gender). In blacks and whites, genotype and allele frequencies did notpausal women were allowed to continue hormone re- differ between genders (P  0.29 for genotype frequency in each race; P  0.28
for allele frequency in each race).placement therapy (HRT). Of the 130 black women, 77
(60%) were postmenopausal of which 29 (38%) were on
HRT. Of the 76 white women, 57 (67%) were postmeno-
pausal of which 35 (69%) were on HRT. Participants
Statistical methodswere required to review and sign a written consent form.
The institutional review boards of Emory University and Genotype and allele frequencies were calculated for
the Mayo Clinic approved all procedures involving sub- each race-gender subgroup. Chi-square contingency tests
jects in Atlanta and Rochester, respectively. All study were used to assess differences in relative frequencies
procedures were carried out in each institution’s General between races in each gender and between genders in
Clinical Research Center (GCRC) in accordance with each race. For quantitative traits, data was initially sum-
the respective institution’s guidelines. marized by calculating means and variances for each
race-gender subgroup. Test statistics with probabilityProtocol
values0.05 were considered statistically significant. Be-
The study protocol has been described [14]. Briefly, cause preliminary analyses found no evidence of statisti-
subjects had their antihypertensive medications with- cally significant interaction between the effects of race
drawn and other contraindicated drugs were discon- and gender on any of the covariate traits (baseline BP,
tinued. A dietitian instructed each subject to ingest a
age, waist-to-hip ratio, plasma renin activity, plasma al-
standard sodium intake of 2 mmol per kg body weight
dosterone concentration, plasma ACE levels, and urineper day. At a minimum of four weeks after discontinuing
aldosterone excretion), results are presented by genderantihypertensive drug therapy, subjects were given 25
(races pooled). Linear regression models were used tomg of HCTZ orally each day for the next four weeks.
assess the dependence of blood pressure responses uponSubjects’ weight, BP, 24-hour urine aldosterone excre-
potential predictor variables. First, we considered ations, and serum potassium concentrations were mea-
model that included the effects of gender, ACE I/Dsured after two and four weeks of diuretic therapy. Oral
genotype, and their interaction. Given the gender speci-potassium supplements (20 to 40 mEq/day) were pre-
ficity of the ACE I/D genotype effect, we next consideredscribed after two weeks of diuretic therapy if serum po-
other potential predictors one-at-a-time in separate mod-tassium was 3.6 mEq/L. At the end of the drug-free
els for women and men. Finally, combinations of theperiod and at the end of the diuretic therapy period,
subjects slept overnight in the GCRC. At approximately univariate predictors were forced into gender specific
6:00 am the next morning, blood for measurement of models to which we subsequently added ACE I/D geno-
plasma aldosterone concentration and renin activity was type.
drawn from subjects in the seated position after a 30-
minute period of ambulation.
RESULTS
Laboratory procedures
Genotype and allele frequencies
Aldosterone concentration and renin activity were de-
Differences in allele frequencies between races weretermined by radioimmunoassay [15]. The ACE I/D poly-
not statistically significant (Table 1). Although the DImorphism was genotyped by a two-stage polymerase
genotype was more common and the II genotype waschain reaction (PCR) amplification of the relevant region
less common in blacks than in whites, these differencesof genomic DNA, followed by restriction enzyme diges-
were of borderline statistical significance (P  0.061).tion, gel electrophoresis, and bromophenol blue staining
In each race, the observed genotype frequencies did notwhich generated a 192 base-pair fragment when the
differ significantly from those predicted by Hardy-Wein-D-allele was present and 479 and 351 base-pair fragments
when the I-allele was present [16, 17]. berg equilibrium (Table 1).
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Table 2. Covariate traits (mean standard deviation)
Genotype
Genotypes
Gender pooled DD DI II P values
Systolic BP Women 15115c 15215a 15015 15116a 0.553
Men 14514 14513 14614 14313 0.464
Diastolic BP Women 965a 966 965 944 0.048
Men 975 974 986 964 0.112
Age Women 496 496 496 496 0.984
Men 488 498 488 478 0.615
Waist/hip Women 0.860.08c 0.850.07c 0.850.08c 0.880.08c 0.058
Men 0.950.06 0.950.06 0.940.06 0.960.07 0.325
PRA Women 1.41.3 1.51.4 1.31.3 1.61.2 0.487
Men 1.41.2 1.51.5 1.31.1 1.61.2 0.463
PAC Women 1910b 208c 1910 2012 0.828
Men 179 147 189 1710 0.035
ACE Women 12.25.0a 15.45.8 11.63.9b 8.03.0 0.0001
Men 13.45.7 16.65.8 13.55.3 9.64.0 0.0001
UAE Women 9.75.8 10.56.5a 9.45.6 9.15.0 0.411
Men 9.46.6 7.66.0 9.85.1 10.79.3 0.066
Abbreviations are: BP, blood pressure in mm Hg; age, in years; PRA, plasma renin activity in ng/mL/hr; PAC, plasma aldosterone concentration in ng/dL; ACE,
angiotensin converting enzyme in U/L; UAE, urinary aldosterone excretion in g per 24 hr. P values given above are for contrasts of means among genotype groups.
Statistical significance for contrasts between genders: aP  0.05; bP  0.01; cP  0.001
Covariate traits
Means for pretreatment systolic and diastolic BP lev-
els, waist-to-hip ratio, plasma aldosterone concentration,
and serum angiotensin-converting-enzyme activity dif-
fered significantly between women and men (Table 2).
These gender differences were not dependent on differ-
ences between races (that is, no evidence of race by
gender interaction; data not shown). Means for diastolic
BP in women, plasma aldosterone concentration in men,
and serum ACE activity in both genders differed signifi-
cantly among genotype groups (Table 2).
Association of blood pressure response with genotype
In women, mean systolic and diastolic BP response to
HCTZ was observed to increase progressively with the
number of I alleles. In contrast, in men, mean systolic
and diastolic BP response to HCTZ was observed to
increase progressively with the number of D alleles (Fig.
1). In linear regression models, we found evidence of
significant interaction between the effects of the ACE
I/D polymorphism and gender on systolic and diastolic
BP responses (for systolic BP, P 0.03; for diastolic BP,
P 0.001). Thus, variation in genotype predicted systolic
and diastolic BP responses to HCTZ in a gender-specific
manner.
Other significant univariate predictors of greater sys-
tolic and diastolic BP responses to HCTZ in both women
and men were higher pretreatment blood pressure levels,
black race, lower pretreatment plasma renin activity, and
Fig. 1. Genotype-specific systolic (A ) and diastolic (B ) blood pressure
lower pretreatment urinary aldosterone excretion (Table (BP) responses to hydrochlorothiazide (HCTZ) therapy in non-His-
panic women (130 blacks, 76 whites) and non-Hispanic men (62 blacks,3). In men, older age was an additional significant pre-
108 whites) with previously diagnosed essential hypertension. The ACEdictor of systolic BP response, and both older age and
I/D genotypes are denoted DD, DI, and II. There was a statistically
lower pretreatment plasma aldosterone concentration significant interaction between the effects of genotype and gender on
systolic and diastolic response (P  0.03 and P  0.001, respectively).were significant predictors of diastolic BP response. In
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Table 3. Univariate predictors of blood pressure
response to hydrochlorothiazide
Systolic response Diastolic response
Predictor Sex R2  100 P value R2  100 P value
Pretreatment BP W 18.6 0.0001 4.1 0.004
M 20.6 0.0001 7.7 0.0001
Race W 6.6 0.0001 1.8 0.058
M 8.0 0.0001 2.9 0.027
Age W 0.5 0.312 0.4 0.392
M 2.8 0.028 4.9 0.004
PRA W 9.2 0.001 5.6 0.001
M 3.9 0.010 3.2 0.020
PAC W 1.5 0.075 0.6 0.276
M 1.4 0.122 4.1 0.008
UAE W 8.6 0.001 3.9 0.004
M 2.2 0.055 2.9 0.027
R2  100 is the percentage of inter-individual variation in blood pressure
response attributable to variation in each predictor trait considered separately.
Abbreviations are: BP, blood pressure; W, women; M, men; PRA, plasma renin
activity; PAC, plasma aldosterone concentration; UAE, urinary aldosterone ex-
cretion.
Fig. 3. Genotype-specific pretreatment urinary aldosterone excretion
(A ) and response of urinary aldosterone excretion (B ) to HCTZ in
non-Hispanic women (130 blacks, 76 whites) and non-Hispanic men
(62 blacks, 108 whites) with previously diagnosed essential hypertension.
The ACE I/D genotypes are denoted DD, DI, and II. There was a
statistically significant interaction between the effects of genotype and
gender on pretreatment urinary aldosterone excretion and on response
of urinary aldosterone excretion to HCTZ therapy (P  0.01 and P 
0.007, respectively).
Fig. 2. Genotype-specific pretreatment serum angiotensin converting
enzyme (ACE) activities in non-Hispanic women (130 blacks, 76 whites) on BP response to HCTZ, we assessed for effects of
and non-Hispanic men (62 blacks, 108 whites) with previously diagnosed the I/D polymorphism on measures of the RAAS. Weessential hypertension. The ACE I/D genotypes are denoted DD, DI,
confirmed the expected relationship between the I/Dand II. ACE activity increased progressively with the number of D
alleles in both women (P  0.001) and men (P  0.001). polymorphism and serum ACE activity, with the D allele
being associated with significantly greater ACE activity
in a co-dominant fashion in women (P  0.001) and
in men (P  0.001; Fig. 2). There was no evidence ofwomen, after considering the effects of race, neither hor-
statistically significant interaction between the effects ofmonal status (premenopausal or postmenopausal on es-
genotype and gender or between genotype and race ontrogen vs. postmenopausal not on estrogen), nor the
serum ACE activity (analyses not shown). In addition,interaction between race and hormonal status were sig-
we found no evidence of an effect of the ACE I/D poly-nificant additional predictors of systolic or diastolic BP
morphism, or of its interaction with gender or race, onresponses. After considering the combined effects of the
pretreatment plasma renin activity or aldosterone con-statistically significant univariate predictors (Table 3),
centration, or the responses of these measures to HCTZthe ACE I/D genotype remained a statistically significant
(analyses not shown).predictor of both systolic and diastolic BP responses in
In contrast, there was evidence of a statistically sig-women (P  0.03 for systolic BP response and P  0.05
nificant interaction between the effects of the ACE I/Dfor diastolic BP response), and diastolic BP response in
polymorphism and gender on pretreatment urinary aldo-men (P  0.002).
sterone excretion and on the response of urinary aldoste-
Association of measures of the RAAS with genotype rone excretion to HCTZ (for pretreatment aldosterone
excretion, P  0.01; for response of aldosterone excre-To explore potential mechanisms for the observed
gender-specific effects of the ACE I/D polymorphism tion to HCTZ, P  0.007; Fig. 3). In each gender, the
Schwartz et al: Genotype and antihypertensive response1722
genotype that was associated with the greatest BP re- tivity, may identify individuals with reduced activity of
the RAAS who are more responsive to HCTZ. Indeed,sponse to HCTZ (II homozygotes in women and DD
homozygotes in men) also was associated with the lowest this was the case in women but not in men in the present
study. One hypothesis consistent with our findings is thaturinary aldosterone excretion and with the greatest in-
crease in urinary aldosterone excretion in response to there may be gender differences in the anti-natriuretic
actions (that is, sodium reabsorption in the proximalHCTZ (Fig. 3). When the effects of HCTZ on urinary
aldosterone excretion were included in gender-specific nephron or aldosterone production from the adrenal
glands) of angiotensin II. In particular, in men, relativelymultiple regression models, variation in the ACE I/D
polymorphism no longer made statistically significant greater anti-natriuretic effects of angiotensin II might
account for a disproportionately greater role of intravas-contributions to the prediction of BP responses to
HCTZ. cular volume in mediating hypertension with increasing
activity of the RAAS (associated with the D allele).
Gender differences in the anti-natriuretic effects of
DISCUSSION
angiotensin II could be mediated by androgens. Studies
Our findings suggest that the I/D polymorphism of the by Reckelhoff, Zhang and Granger demonstrate that
ACE gene is associated with interindividual differences pressure-natriuresis is blunted in male SHR compared to
in BP response to a standard dose of a thiazide diuretic in females [20]. Castration of male SHR restored pressure-
a gender specific manner. These relationships persisted natriuresis, whereas ovariectomy of female SHR had no
after adjustment for race, age, and measures of body effect [20]. Treatment of ovariectomized female SHR
size, which are traditional predictors of response. As in with testosterone was associated with blunting of pres-
previous studies [6], ACE activity increased in a co- sure-natriuresis [18]. Recent evidence has shown that
dominant fashion in association with the D allele in both the androgen receptor is predominantly located in the
genders. Consequently, the effects of the I/D polymor- proximal nephron segments (abstract; Hennington et al,
phism on ACE activity per se cannot explain the gender- Hypertension 30:510, 1997). These data suggest that in
specific effects of the polymorphism on BP response to males, androgens may increase proximal sodium reab-
HCTZ. sorption, possibly by facilitating the action of angiotensin
In both genders, the genotypes that were associated II. Androgens also may enhance the effect of angiotensin
with the greatest decline in BP (that is, the II homozy- II to increase aldosterone production. Miller, Anacta
gotes in women and the DD homozygotes in men) also and Cattran found higher aldosterone levels in men than
were associated with the lowest pretreatment urinary in women [21] and Schunkert et al found a positive corre-
aldosterone excretion and the greatest increase in uri- lation between a metabolite of testosterone and aldoste-
nary aldosterone excretion in response to HCTZ. This rone in a sample of hypertensive men [22].
consistency lessens the likelihood of spurious gender That the most responsive genotypes also were charac-
specificity of the relationship between the ACE I/D poly- terized by lower pretreatment urinary aldosterone excre-
morphism and BP responses to HCTZ. In men, the ob- tion and greater increases in urinary aldosterone excre-
servation that urinary aldosterone excretion was lower tion in response to HCTZ suggests that the responsive
in DD homozygotes than in II homozygotes may appear genotypes in each gender have volume dependent hyper-
internally inconsistent given a possible association be- tension. Lower pretreatment urinary aldosterone excre-
tween ACE activity and angiotensin II levels; however, tion may mark a relatively greater role of increased intra-
the lack of correlation of aldosterone secretion with vascular volume as a determinant of BP level, and a
proximal measures of the RAAS (plasma renin activity, greater increase in urinary aldosterone excretion with
ACE levels) has been reported [18, 19]. After the effects treatment may mark a more effective intravascular vol-
of HCTZ treatment on aldosterone excretion were con- ume contraction resulting in a greater BP response.
sidered, the ACE I/D polymorphism made no additional In addition to the speculative nature of our hypothesis
contribution to prediction of BP response in either gen- to explain the gender specificity of the relationship be-
der. This latter finding suggests that the observed gender- tween the ACE I/D polymorphism and BP response to
specificity in the relationship between the I/D poly- HCTZ, this study has several limitations. First, the study
morphism and BP response to HCTZ may be mediated was not designed with the expectation of testing or find-
subsequent to the generation of angiotensin II. ing gender-specific effects. Second, gender could be a
Low plasma renin activity is a predictor of greater BP surrogate marker for characteristics other than sex hor-
response to thiazide diuretics [2, 3]. Low plasma renin mones that were not identified or measured and are
activity suggests both reduced activity of the RAAS and responsible for the effects attributed to gender. Third,
a greater role of intravascular volume in determination the ACE I/D polymorphism may simply be a marker of
of blood pressure level. The I allele of the ACE I/D variation elsewhere in the ACE gene or a nearby gene
that is responsible for the observed effects. Finally, givenpolymorphism, by being associated with lower ACE ac-
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the gene for angiotensin-converting-enzyme is a potent risk factorthe relatively small size of the homozygote groups, our
for myocardial infarction. Nature 359:641–644, 1992
findings could be due to an unrecognized bias in the 8. Iwai N, Ohmichi N, Nakamura Y, Kinoshita A: DD genotype of
the angiotensin-converting-enzyme is a risk factor for left ventricu-sample, not controlled for by our statistical analyses.
lar hypertrophy. Circulation 90:2622–2628, 1994Therefore, given these caveats, confirmatory studies are
9. Markus HS, Barley J, Lunt R, et al: Angiotensin-converting
indicated. enzyme gene deletion polymorphism. A new risk factor for lacunar
stroke but not carotid atheroma. Stroke 26:1329–1333, 1995Notwithstanding these caveats, this study suggests that
10. Mallamaci F, Zuccala A, Zoccali C, et al: The deletion polymor-the ACE I/D polymorphism predicts BP response to a phism of the angiotensin-converting enzyme is associated with
thiazide diuretic in a gender-specific manner and that nephroangiosclerosis. Am J Hypertens 13(4 Pt 1):433–437, 2000
11. O’Donnell CJ, Lindpainter K, Larson MG, et al: Evidence forthis effect is additive to known predictors of BP response.
association and genetic linkage of the angiotensin-converting en-This study demonstrates the potential of pharmaco- zyme locus with hypertension and blood pressure in men but not
genetic knowledge to provide insights into the heteroge- women in the Framingham Heart Study. Circulation 97:1766–1772,
1998neous pathophysiology of antihypertensive responses, in
12. Turner, ST, Boerwinkle E, Sing CF: Context-dependent associa-
particular differences between genders. tions of the ACE I/D polymorphism with blood pressure. Hyperten-
sion 34(4 Pt 2):773–778, 1999
13. Kimura M, Yokota M, Fujimura T, et al: Association of a deletionACKNOWLEDGMENTS polymorphism of the converting enzyme gene with left-ventricular
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multicenter study of 1919 subjects. Cardiology 88:309–314, 1997HL5330, M01-RR00039, M01-RR00585, and funds from the Mayo
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